Phaseline

Targets › HTR7

HTR7 (5-hydroxytryptamine receptor 7): drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 1; Other.

G protein-coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors. (UniProt, P34969)

Open in Phaseline: the race on HTR7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital, Basel, SwitzerlandDMT
5-HT receptor agonist, primarily 5-HT1A and 5-HT7
HTR1A, HTR1B, HTR1D, HTR5A, HTR7Phase 1Healthy–
University Hospital, Basel, SwitzerlandLSD
5-HT receptor agonist, primarily 5-HT1A and 5-HT7
HTR1A, HTR1B, HTR1D, HTR5A, HTR7Phase 1Healthy–

Conditions

Healthy (2)

Modalities

small molecule (2)

Companies

University Hospital, Basel, Switzerland (2)

Related targets

HTR1A (2) HTR1B (2) HTR1D (2) HTR5A (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.